Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
3.910
-0.100 (-2.49%)
At close: Jul 25, 2025, 4:00 PM
4.030
+0.120 (3.07%)
After-hours: Jul 25, 2025, 7:43 PM EDT
Company Description
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.
Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation.
The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
The company is headquartered in San Diego, California.
Skye Bioscience, Inc.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Punit Dhillon |
Contact Details
Address: 11250 El Camino Real, Suite 100 San Diego, California 92130 United States | |
| Phone | 858 410 0266 |
| Website | skyebioscience.com |
Stock Details
| Ticker Symbol | SKYE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001516551 |
| CUSIP Number | 83086J101 |
| ISIN Number | US83086J2006 |
| Employer ID | 45-0692882 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Punit S. Dhillon B.A. | President, Chief Executive Officer, Secretary and Director |
| Kaitlyn Melanie Arsenault CPA | Chief Financial Officer |
| Tu Diep M.Sc. | Chief Operating Officer |
| Dr. Christopher G. Twitty Ph.D. | Chief Scientific Officer |
| Brennen Brodersen J.D. | General Counsel |
| Dr. Puneet S. Arora FACE, M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 11, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 8, 2025 | 8-K | Current Report |
| May 8, 2025 | 10-Q | Quarterly Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2025 | SCHEDULE 13G/A | Filing |
| Mar 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 20, 2025 | 8-K | Current Report |